| Abbott (23) |  |
| Amgen (10) | |
| Astra-merck (6) | |
| Bayer (41) | |
| Boehringer-ingelheim (1) | |
| Bristol-myers-squibb (5) | |
| Dupont-merck (14) | |
| Eli lilly (5) | |
| Genentech (5) | |
| Genzyme (5) | |
| Glaxosmithkline (26) | |
| Hoechst-marion-roussel (4) | |
| Pasteur-merieux (8) | |
| Pfizer (22) | |
| Pharmaceutical industry (36) | |
| Pharmaceutical laboratory (1) | |
| Pharmacyclics (1) | |
| Roche pharmaceuticals (16) | |
| Sanofi-aventis (6) | |
| Stallergenes (1) | |
| Whitehall laboratories (3) | |
Hepatitis C hopefuls Pharmaceutical giant Bristol-myers squibb of New york city has become the latest company to spend billions on the promise of hepatitis C treatments.
Jeremy Levin, former head of strategy and alliances at Bristol-myers squibb in New york city, has a reputation for making external partnerships
Bristol-myers squibb and Astrazeneca, are teaming up to acquire the biotech firm Amylin, based in San diego, California, for US$5. 3 Â billion (or $7 Â billion with existing contractual obligations).
Bristol-myers squibb, headquartered in New york city, is buying Amylin for its lucrative diabetes treatments. As part of the deal, announced on 29 Â June,
Weve worked with Amgen, Bristol-myers squibb, usually biotech or pharmaceutical companies. Weve also worked with companies in the forestry industry.
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011